RioDerm-004 by Rion for Fistula: Likelihood of Approval

RioDerm-004 is under clinical development by Rion and currently in Phase I for Fistula.

Invenra’s antibody gains FDA designations for neuroblastoma

Invenra’s bispecific antibody is under development to treat neuroblastoma. Credit: Kateryna Kon/Shutterstock. Invenra has received rare pediatric disease designation (RPDD) and orphan drug designation (ODD)

August 26, 2024

Federal Government Unveils Draft Health IT Strategy for Public Comment

What You Should Know: – The Office of the National Coordinator for Health Information Technology (ONC)is seeking public input on a new draft plan outlining

March 27, 2024

Beyond Credentialing: How PDM Drives Quality Care & Revenue

Bill Christy, SVP and Managing Director of Provider Data Management Solutions at symplr As healthcare costs continue to rise and workforce shortages reach a critical level,

February 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.